METRIX
Brief summary
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 80%-85% of lung cancers cases of which 60% are non-squamous (NSQ). This study will evaluate the prevalence of mesenchymal epithelial transition (MET) overexpression (OE) in adult participants with advanced or metastatic NSQ NSCLC. Archived tissue biopsies will be tested for MET OE and data from approximately 500 participants will be collected. No participants will be enrolled in this study. Participants' charts will be reviewed. No drug will be administered as a part of this study. The duration of the study will be approximately 15 months. There is no additional burden for participants in this trial.
Observational study
Would you like to know more about this trial?
|
Please note, participation in the clinical trial is open to patients with the disease or condition under investigation. |
Age:
18 Years and older.
Inclusion Criteria:
- Previously consented and/or prospective collection of consent for research use of
banked biological materials and clinical data.
- Confirmed advanced and/or metastatic non-squamous (NSQ) non-small cell lung cancer
(NSCLC).
- Has formalin-fixed paraffin-embedded (FFPE) tissue collected since 2019.
Exclusion Criteria:
- Specimens collected before 2019.
- Insufficient specimen tissue for testing.
- Insufficient specimen quality (e.g., not 4-5 µm in thickness) which precludes testing.
- Adenosquamous and sarcomatous histologies of NSCLC.
